Default company panoramic image
790948d0 9d5a 4f14 b691 c5a93da8a0eb

Medicus Biosciences

Medicus has patented minimally invasive drug delivery platform for multibillion dollar markets of lung cancer and other chronic disease.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded July 2009
  • Employees 2

Company Summary

Medicus has selected lung cancer as the initial market. Each year 160,000 people die of lung cancer in the US and 1.18 million people worldwide. The infrastructure and technical expertise for instilling Medicus’ solution are already in place, paving the way for rapid adoption worldwide. In addition, Medicus has identified a wide range of potential applications including the treatment of mesothelioma, ovarian and bladder cancer, and tuberculosis.


  • Default avatar
    Dan Nathanson

    Dr. Nathanson is an entrepreneur, executive, investor, consultant and educator. He has a 25-year record of success in building businesses, creating financial value and helping entrepreneurs succeed. Dr. Nathanson is currently a Professor at the UCLA Anderson School of Management and serves as the Managing Director of SJ Investment Company (SJIC), an investment fund providing capital, oversight and direction to early stage companies.

  • Default avatar
    Syed Askari

    Dr. Askari was the Head of Polymer Chemistry R&D at 3 separate start-up companies and has developed the key polymer technologies for FDA approved biomaterials at those companies. One of the start-up companies was acquired by a very large established company for approximately $1 billion. Another startup company has acquired a major market share immediately upon FDA approval. Dr. Askari has thirteen (13) patents or patent applications in the field.

  • Default avatar
    George Horng

    Dr. Horng is a physician-scientist board certified in Internal Medicine, Pulmonary Medicine, and Critical Care Medicine. He is a partner in the San Francisco Critical Care Medical Group and an Associate Director of the Pulmonary/Critical Care Fellowship Program at California Pacific Medical Center (CPMC). He is also a member of the Thoracic Oncology Tumor Board and co-investigator of the Pulmonary Nodule Clinic Study at CPMC.

  • Default avatar
    Warren Grundfest
    Chief Advisor

    Dr. Warren Grundfest, one of the 100 Notable People in medical device industry, is Chairman of the Biomedical Engineering Interdepartmental Graduate Program at the University of California, Los Angeles, School of Engineering and is Assistant Clinical Professor of Surgery at UCLA, School of Medicine. He is Director of Laser Research & Technology Development Program and Attending General Surgery at Cedar-Sinai Medical Center.


  • Default avatar
    Wilson Sonsini
    Default avatar
    Tim Dennison

Previous Investors

  • Default avatar
    SJ Investment Company